Thursday, July 1, 2010

Dendreon重挫, 逢低吸纳

Dendreon重挫,联邦医疗保险称正在评估其医疗数据. 在$30下不妨逢低吸纳. 该机构无议价权，虽然DNDN药物昂贵，仍在法定范围内; DNDN有能力生产上市，不需要合作者.
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)